A prospective study on the prevalence of MASLD in people with type‐2 diabetes in the community. Cost effectiveness of screening strategies
Abstract Background and Aims As screening for the liver disease and risk‐stratification pathways are not established in patients with type‐2 diabetes mellitus (T2DM), we evaluated the diagnostic performance and the cost‐utility of different screening strategies for MASLD in the community. Methods Consecutive patients with T2DM from primary care underwent screening for liver diseases, ultrasound, ELF score and transient elastography (TE). Five strategies were compared to the standard of care: ultrasound plus abnormal liver function tests (LFTs), Fibrosis score‐4 (FIB‐4), NAFLD fibrosis score, Enhanced liver fibrosis test (ELF) and TE. Standard of care was defined as abnormal LFTs prompting referral to hospital. A Markov model was built based on the fibrosis stage, defined by TE. We generated the cost per quality‐adjusted life year (QALY) gained and calculated the incremental cost‐effectiveness ratio (ICER) over a lifetime horizon. Results Of 300 patients, 287 were included: 64% (186) had MASLD and 10% (28) had other causes of liver disease. Patients with significant fibrosis, advanced fibrosis, and cirrhosis due to MASLD were 17% (50/287), 11% (31/287) and 3% (8/287), respectively. Among those with significant fibrosis classified by LSM≥8.1 kPa, false negatives were 54% from ELF and 38% from FIB‐4. On multivariate analysis, waist circumference, BMI, AST levels and education rank were independent predictors of significant and advanced fibrosis. All the screening strategies were associated with QALY gains, with TE (148.73 years) having the most substantial gains, followed by FIB‐4 (134.07 years), ELF (131.68 years) and NAFLD fibrosis score (121.25 years). In the cost‐utility analysis, ICER was £2480/QALY for TE, £2541.24/QALY for ELF and £2059.98/QALY for FIB‐4. Conclusion Screening for MASLD in the diabetic population in primary care is cost‐effective and should become part of a holistic assessment. However, traditional screening strategies, including FIB‐4 and ELF, underestimate the presence of significant liver disease in this setting..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:44 |
|---|---|
| Enthalten in: |
Liver International - 44(2024), 1, Seite 61-71 |
| Beteiligte Personen: |
Forlano, Roberta [VerfasserIn] |
|---|
| Anmerkungen: |
© 2024 John Wiley & Sons A/S |
|---|
| Umfang: |
11 |
|---|
| doi: |
10.1111/liv.15730 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY017953189 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY017953189 | ||
| 003 | DE-627 | ||
| 005 | 20240422220319.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240422s2024 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1111/liv.15730 |2 doi | |
| 028 | 5 | 2 | |a 2024-04-22_LIV_2024_44_1.zip.xml |
| 035 | |a (DE-627)WLY017953189 | ||
| 035 | |a (WILEY)LIV15730 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 100 | 1 | |a Forlano, Roberta |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a A prospective study on the prevalence of MASLD in people with type‐2 diabetes in the community. Cost effectiveness of screening strategies |
| 264 | 1 | |c 2024 | |
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2024 John Wiley & Sons A/S | ||
| 520 | |a Abstract Background and Aims As screening for the liver disease and risk‐stratification pathways are not established in patients with type‐2 diabetes mellitus (T2DM), we evaluated the diagnostic performance and the cost‐utility of different screening strategies for MASLD in the community. Methods Consecutive patients with T2DM from primary care underwent screening for liver diseases, ultrasound, ELF score and transient elastography (TE). Five strategies were compared to the standard of care: ultrasound plus abnormal liver function tests (LFTs), Fibrosis score‐4 (FIB‐4), NAFLD fibrosis score, Enhanced liver fibrosis test (ELF) and TE. Standard of care was defined as abnormal LFTs prompting referral to hospital. A Markov model was built based on the fibrosis stage, defined by TE. We generated the cost per quality‐adjusted life year (QALY) gained and calculated the incremental cost‐effectiveness ratio (ICER) over a lifetime horizon. Results Of 300 patients, 287 were included: 64% (186) had MASLD and 10% (28) had other causes of liver disease. Patients with significant fibrosis, advanced fibrosis, and cirrhosis due to MASLD were 17% (50/287), 11% (31/287) and 3% (8/287), respectively. Among those with significant fibrosis classified by LSM≥8.1 kPa, false negatives were 54% from ELF and 38% from FIB‐4. On multivariate analysis, waist circumference, BMI, AST levels and education rank were independent predictors of significant and advanced fibrosis. All the screening strategies were associated with QALY gains, with TE (148.73 years) having the most substantial gains, followed by FIB‐4 (134.07 years), ELF (131.68 years) and NAFLD fibrosis score (121.25 years). In the cost‐utility analysis, ICER was £2480/QALY for TE, £2541.24/QALY for ELF and £2059.98/QALY for FIB‐4. Conclusion Screening for MASLD in the diabetic population in primary care is cost‐effective and should become part of a holistic assessment. However, traditional screening strategies, including FIB‐4 and ELF, underestimate the presence of significant liver disease in this setting. | ||
| 700 | 1 | |a Stanic, Tijana |4 aut | |
| 700 | 1 | |a Jayawardana, Sahan |4 aut | |
| 700 | 1 | |a Mullish, Benjamin Harvey |4 aut | |
| 700 | 1 | |a Yee, Michael |4 aut | |
| 700 | 1 | |a Mossialos, Elias |4 aut | |
| 700 | 1 | |a Goldin, Robert |4 aut | |
| 700 | 1 | |a Petta, Salvatore |4 aut | |
| 700 | 1 | |a Tsochatzis, Emmanouil |4 aut | |
| 700 | 1 | |a Thursz, Mark |4 aut | |
| 700 | 1 | |a Manousou, Pinelopi |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Liver International |g 44(2024), 1, Seite 61-71 |w (DE-627)WLY009720367 |x 14783231 |7 nnns |
| 773 | 1 | 8 | |g volume:44 |g year:2024 |g number:1 |g pages:61-71 |g extent:11 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 951 | |a AR | ||
| 952 | |d 44 |j 2024 |e 1 |h 61-71 |g 11 | ||